Prime Medicine
Prime Medicine is a biotechnology company developing gene editing therapies based on Prime Editing technology, a next-generation gene editing approach designed to 'search and replace' precise locations in the genome to correct disease-causing DNA mutations. The company was co-founded by David Liu of the Broad Institute and Harvard University and Andrew Anzalone, who developed the Prime Editing technology. Following a May 2025 strategic restructuring, Prime Medicine is focused on genetic liver diseases (Wilson's Disease and Alpha-1 Antitrypsin Deficiency), cystic fibrosis, and partnered programs including a CAR-T collaboration with Bristol Myers Squibb.
Public Company
Prime Medicine is publicly traded
IPO'd on October 20, 2022
This company is no longer available on our private secondary market. Shares can be traded publicly under PRME.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2019
Employees
200–300
Total Funding
$634.2M
3 rounds
Last Private Valuation
$1.2B
March 9, 2021
Funding
Total raised $634.2M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
IPO
Date
November 10, 2021
Amount
$175M
Valuation
$1.7B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| November 10, 2021 | IPO | $175M | $1.7B | Public investors |
| March 9, 2021 | Series B | $200M | $1.2B | |
| 2020 | Series A | $115M | — | ARCH Venture Partners, GV, Newpath Partners +1 more |
Valuation Trajectory
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Series B
$1.2B
Mar 2021
Prime Medicine today
$1.7B
Nov 2021 · latest mark
Prime Medicine multiple
1.4x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Prominent Investors
Leadership
Allan Reine
Chief Executive Officer
Jeffrey D. Marrazzo
Executive Chair of the Board
Svetlana Makhni
Chief Financial Officer
Matthew Hawryluk
Chief Business Officer
David Liu
Co-Founder, Scientific Advisor
Andrew Anzalone
Co-Founder
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Beam Therapeutics
Public gene editing company developing precision base editing therapeutics; directly overlaps with Prime Medicine in AATD and other genetic diseases.
Editas Medicine
Public CRISPR gene editing company developing Cas9 and Cas12a-based genomic medicines for oncological and hematological disorders.
Intellia Therapeutics
Public CRISPR gene editing company developing in-vivo and ex-vivo therapies, including Phase 3 assets for ATTR amyloidosis.
CRISPR Therapeutics
Public CRISPR gene editing company that markets Casgevy for sickle cell disease and beta-thalassemia.
Caribou Biosciences
Public CRISPR gene editing company developing allogeneic cell therapies for cancer and other diseases.
Prime Medicine Investment FAQ
Prime Medicine FAQ
Yes, Prime Medicine is publicly traded under the ticker symbol PRME on the Nasdaq. The company went public in October 20, 2022.
Prime Medicine trades under the ticker symbol PRME on the Nasdaq. It began trading in October 20, 2022.
Prime Medicine (PRME on the Nasdaq) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker PRME to place an order.
Prime Medicine went public in October 20, 2022 via ipo, with an offering valuation of approximately $1.2B. Prime Medicine completed its initial public offering on October 20, 2022, listing on Nasdaq under the ticker PRME at $17.00 per share, raising approximately $175 million in gross proceeds.
Prime Medicine raised $634.2M across 3 disclosed funding rounds prior to its public listing.
Prime Medicine was co-founded by David Liu, and Andrew Anzalone in 2019.
Prime Medicine is headquartered in Cambridge, MA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.